Höckel M, Schlenger K, Doctrow S, Kissel T, Vaupel P
Department of Obstetrics and Gynecology, University of Mainz, Germany.
Arch Surg. 1993 Apr;128(4):423-9. doi: 10.1001/archsurg.1993.01420160061009.
We have proposed the term "therapeutic angiogenesis" to describe the induction or stimulation of neovascularization for the treatment or prevention of pathological clinical situations characterized by local hypovascularity. Evidence also shows that "clinically normal" healing and tissue regeneration can be improved or accelerated by therapeutic angiogenesis. Traditionally, therapeutic angiogenesis has been achieved by surgical methods, ie, the transposition of autologous tissues with uncompromised vasculature and high angiogenic potential such as omentum majus flaps and muscle flaps. Recent advances in the understanding of the biological process of neovascularization as well as the discovery and cloning of angiogenic cytokines may add a new clinical tool: therapeutic angiogenesis by pharmaceutical methods. Based on the results of animal studies and preliminary clinical trials, this review is aimed to give a state-of-the-art compilation of (1) those angiogenesis factors that appear promising in clinical application for therapeutic angiogenesis and (2) the surgical indication fields with near-term potential for therapeutic angiogenesis by use of angiogenic cytokines.
我们提出了“治疗性血管生成”这一术语,用于描述诱导或刺激新血管形成,以治疗或预防以局部血管减少为特征的病理性临床情况。有证据表明,“临床正常”的愈合和组织再生也可以通过治疗性血管生成得到改善或加速。传统上,治疗性血管生成是通过手术方法实现的,即移植具有完整血管系统和高血管生成潜力的自体组织,如大网膜瓣和肌瓣。对新血管形成生物学过程的理解以及血管生成细胞因子的发现和克隆方面的最新进展,可能会增加一种新的临床工具:药物治疗性血管生成。基于动物研究和初步临床试验的结果,本综述旨在对以下内容进行最新的汇总:(1)那些在治疗性血管生成的临床应用中看起来有前景的血管生成因子,以及(2)通过使用血管生成细胞因子在近期具有治疗性血管生成潜力的手术适应症领域。